All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can we address treatment disparities in patients with T-cell lymphoma?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Mary Jo Lechowicz, Winship Cancer institute of Emory University, Atlanta, US. We asked, How can we address treatment disparities in patients with T-cell lymphoma?

How can we address treatment disparities in patients with T-cell lymphoma?

Lechowicz begins by outlining some reasons for these disparities and stresses the importance of international collaboration. She then discusses social determinants for health and current multi center studies, emphasizing that collaboration and communication are key factors.

 

Share: